Though, in melanoma, adjuvant bevacizumab did not show survival benefit in a phase 3 clinical trial [38], combining anti-VEGF therapies with immunotherapy appears to be an active regimen in advanced melanoma [39]. Here, VEGFA is linked to melanoma.